Insertion of the Asp-Ser/Phe sequence in the P' position of hirutonin provides molecules having both antithrombin and disintegrin activity

Thrombosis Research

Volumn 93, Issue 4, 1999, Pages 171-181

  Leblond, Lorraine ^a   Dimaio, John ^a   Winocour, Peter D ^a  

^a Shire Canada   (Canada)

Author keywords

Adhesion; GpIIbIIIa inhibitor; Hirutonin; Hybrid molecule; Thrombin inhibitor

Indexed keywords

ANTITHROMBIN; ARGINYLGLYCYLASPARTIC ACID; DISINTEGRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; SEROTONIN; SYNTHETIC PEPTIDE; THROMBIN; THROMBIN INHIBITOR; VITRONECTIN;

ANTICOAGULATION; ARTICLE; CELL ADHESION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYBRID; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECEPTOR BINDING; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTITHROMBINS; CELL ADHESION; DISINTEGRINS; HIRUDINS; HUMANS; MICE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033558011     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00182-0     Document Type: Article

References (45)

1. Ruggeri Z.M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 31:1994;229-239.
2. Plow E.F., D'Souza S.E., Ginsberg M.H. Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa (αIIbβ3) and its ligands. J Lab Clin Med. 120:1992;198-204.
3. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade. Initiation, maintenance, and regulation Biochemistry. 30:1991;10363-10370.
4. Mann K.G., Lawson J.H. The role of the membrane in the expression of the vitamin K-dependent enzymes. Arch Pathol Lab Med. 116:1992;1330-1336.
5. Cook N.S., Kottirsch G., Zerwes H.-G. Platelet glycoprotein IIb|IIIa antagonists. Drugs of the Future. 19:1994;135-159.
6. Coller B.S., Anderson K.M., Weisman H.F. The anti-GpIIb-IIIa agents. Fundamental and clinical aspects Haemostasis. 26:1996;285-293.
7. Tcheng J.E. Glycoprotein IIb|IIIa receptor inhibitors. Putting the EPIC, IMPACTII, RESTORE, and EPILOG trials into perspective Am J Cardiol. 78:1996;35-40.
8. Coutré S., Leung L. Novel antithrombotic therapeutics targeted against platelet glycoproteins IIb/IIIb. Annu Rev Med. 16:1995;257-265.
9. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 74:1994;1-23.
10. Maraganore J.M., Bourdon P., Jablonski J., Ramachandran K.L., Fenton J.W. Design and characterization of hirulogs. A novel class of bivalent peptide inhibitors of thrombin Biochemistry. 29:1990;7095-7101.
11. Finkle C.D., St-Pierre A., Leblond L., Deschesnes I., DiMaio J., Winocour P.D. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 79:1998;431-438.
12. Kimball S.D. Challenges in the development of orally biovailable thrombin active site inhibitors. Blood Coag Fibrinol. 6:1995;511-519.
13. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coron Artery Dis. 8:1997;105-111.
14. Imura Y., Stassen J.-M., Vreys I., Lesaffre E., Gold H.K., Collen D. Synergistic antithrombin properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost. 68:1992;336-340.
15. Church F.C., Phillips J.E., Woods J.L. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)-and hirudin carboxyl terminus-containing synthetic peptide. J Biol Chem. 266:1991;11975-11979.
16. Knapp A., Degenhardt T., Dodt J. Hirudisins. Hirudin-derived inhibitors with disintegrin activity. J Biol Chem. 267:1992;24230-24234.
17. Phaneuf M.D., Ozaki C.K., Johnstone M.T., Loza J.P., Quist W.C., LeGerfo F.W. Covalent linkage of streptokinase to recombinant hirudin. A novel thrombolytic agent with antithrombotic properties Thromb Haemost. 71:1994;481-487.
18. Lijnen H.R., Wnendt S., Schneider J., Janocha E., Van Hoef B., Collen D., Steffens G.J. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. Eur J Biochem. 234:1995;350-357.
19. Yamada T., Shimada Y., Kikuchi M. Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Biochem Biophys Res Comm. 228:1996;306-311.
20. Maksimenko A.V., Petrov A.D., Tischenko E.G., Smirnov M.D. Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase. Ann NY Acad Sci. 750:1995;496-501.
21. Schneider J., Hauser R., Hennies H.-H., Steffens G., Wnendt S. A novel chimaeric derivative of Saruplase, rscu-PA-40kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs. Thromb Haemost. 77:1997;535-539.
22. Gurevich V.S., Lominadze D.G., Adeagbo A.S.O., Burov S.V., Popov Y.G., Leko M.V., Miller F.N., Schuschke D.A. Antithrombotic and vasorelaxant properties of a novel synthetic RGD peptide containing nitric oxide. Pharmacology. 55:1997;1-9.
23. DiMaio J., Ni F., Gibbs B., Konishi Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Lett. 282:1991;47-52.
24. DiMaio J., Gibbs B., Lefebvre J., Konishi Y., Munn D., Yue S.Y. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem. 5:1992;3331-3341.
25. Phillips D.R., Fitzgerald L., Parise L., Steiner B. Platelet membrane glycoprotein IIbIIIa complex. Purification, characterization, and reconstitution into phospholipid vesicles Methods in Enzymol. 215:1992;244-263.
26. Tranqui L., Andrieux A., Hudry-Clergeon G., Ryckewaert J.-J., Soyez S., Chapel A., Ginsberg M.H., Plow E.F., Marguerie G. Differential structural requirements for fibrinogen binding to platelets and to endothelial cells. J Cell Biol. 108:1989;2519-2527.
27. DiMaio J., Gibbs B., Munn D., Lefebre J., Konishi Y. Bifunctional thrombin inhibitors based on the sequence of hirudin. J Biol Chem. 265:1990;21698-21703.
28. Szewczuk Z., Gibbs B.F., Yue S.Y., Purisima E.O., Konishi Y. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion. Biochemistry. 31:1992;9132-9140.
29. Mustard J.F., Perry D.W., Ardie N.G., Packham M.A. Preparation of suspensions of washed platelets from humans. Br J Haematol. 22:1972;193-204.
30. Holmsen H., Dangelmaier C.A. Measurement of secretion of serotonin. Methods Enzymol. 169:1989;206-210.
31. Charo I.F., Nannizzi L., Phillips D.R., Hsu M.A., Scarborough R.M. Inhibition of fibrinogen binding to GpIIb-IIIa by GP IIIa peptides. J Biol Chem. 266:1991;1415-1421.
32. Staiano N., Villani G.R.D., Di Martino E., Squillacioti C., Vuotto P., Di Natale P. Echistatin inhibits the adhesion of murine melanoma cells to extracellular matrix components. Biochem Mol Biol Int. 35:1995;11-19.
33. Dodt J., Kohler S., Schmitz T., Wilhelm B. Distinct binding sites of Ala48-hirudin 1-47 and Ala48-hirudin 48-65 on α-thrombin. J Biol Chem. 265:1990;713-718.
34. Alig L., Edenhofer A., Hadvary P., Hürzeler M., Knopp D., Müller M., Steiner B., Trzeciak A., Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem. 35:1992;4393-4407.
35. 3 in tumor cells from various species and histological origin. Int J Cancer. 72:1997;642-648.
36. Finkle C., DiMaio J., Tarazi M., Leblond L., Winocour P.D. A new potent direct acting thrombin inhibitor is an effective inhibitor of arterial thrombosis in rats. FASEB J. 10:1996;A1414.
37. Coughlin S.R. Molecular mechanism of thrombin signaling. Semin Hematol. 31:1994;270-277.
38. 3) function via the thrombin receptor. Biochem J. 309:1995;613-620.
39. Rand M.L., Perry D.W., Packham M.A., Gemmell C.H., Yeo E.L., Kinlough-Rathbone R.L. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN. Direct measurement of percent release of β-thromboglobulin and assessment by flow cytometry of P-selectin expression Am J Hematology. 52:1996;288-294.
40. Pierschbacher M.D., Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xxx on binding specificity in cell adhesion. J Biol Chem. 262:1987;17294-17298.
41. Gurrath M., Muller G., Kessker H., Aumailley M., Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem. 270:1992;911-921.
42. Peishoff C.E., Ali F.E., Bean J.W., Calvo R., D'Ambrosio C.A., Eggleston D.S., Hwang S.M., Kline T.P., Koster P.F., Nichols A., Powers D., Romoff T., Samanen J.M., Stadel J., Vasko J.A., Kopple K.D. Investigation of conformational specificity at GpIIbIIIa. Evaluation of conformationally constrained RGD peptides J Med Chem. 35:1992;3962-3969.
43. 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Biochem J. 312:1995;223-232.
44. 3. J Biol Chem. 270:1995;30486-30490.
45. Le Bonniec B.F., Myles T., Johnson T., Knight C.G., Tapparelli C., Stone S.R. Characterization of the P2′ and P3′ specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Biochemistry. 35:1996;7114-7122.